Treatment for CNS Hyperarousal After CBT-I Failure

Introduction to Hyperarousal Treatment

The American Academy of Sleep Medicine recommends considering low-dose pregabalin (75-150 mg at bedtime) or low-dose doxepin (3-6 mg) for patients with persistent CNS hyperarousal despite adequate CBT-I, as these target hyperarousal mechanisms rather than providing sedation 1, 2.

Low-dose doxepin (3-6 mg) targets histamine H1 receptors to reduce arousal without the anticholinergic burden of higher doses, and is preferred when comorbid depression/anxiety exists, as it may address both conditions 1, 2, 3.
The American Academy of Sleep Medicine suggests that ramelteon 8 mg works through melatonin receptor agonism to normalize circadian arousal patterns without sedation, and is particularly useful when hyperarousal has a circadian dysregulation component 1, 2.

The American Academy of Sleep Medicine recommends avoiding traditional sedative-hypnotics, such as benzodiazepine receptor agonists and benzodiazepines, as they provide sedation without addressing underlying hyperarousal, and carry risks of tolerance, dependence, cognitive impairment, and complex sleep behaviors 1, 2, 3.
The American Academy of Sleep Medicine also recommends avoiding over-the-counter antihistamines, such as diphenhydramine, due to lack of efficacy data and significant safety concerns, including anticholinergic effects and daytime sedation 2, 3, 4.

The American Academy of Sleep Medicine suggests that pharmacotherapy must supplement, not replace, behavioral interventions, even when CBT-I has been "unsuccessful", and recommends re-evaluating CBT-I implementation and considering trait arousal-specific modifications 1, 3, 5.

The treatment algorithm involves verifying CBT-I adequacy, ruling out occult comorbidities, initiating pregabalin or doxepin, titrating after 1 week, reassessing at 4 weeks, and considering switching to ramelteon or combining low-dose doxepin with ramelteon if inadequate response 1, 2, 3, 4.

The American Academy of Sleep Medicine recommends monitoring sleep diary data throughout treatment, daytime arousal symptoms, side effects, and reassessing every 2-4 weeks initially, then every 6 months given high relapse rates 1, 3, 6.